{"nctId":"NCT00091819","briefTitle":"Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus","startDateStruct":{"date":"2005-01"},"conditions":["Staphylococcal Skin Infection"],"count":862,"armGroups":[{"label":"Telavancin","type":"EXPERIMENTAL","interventionNames":["Drug: Telavancin"]},{"label":"Vancomycin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Vancomycin"]}],"interventions":[{"name":"Telavancin","otherNames":["VIBATIV","TD-6424"]},{"name":"Vancomycin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients must have a diagnosis of one of the following complicated skin and skin structure infections with Methicillin Resistant Staphylococcus aureus (MRSA) either suspected or confirmed as the major cause of the infection:\n\n  * major abscess requiring surgical incision and drainage\n  * infected burn (see exclusion criteria for important qualifications)\n  * deep/extensive cellulitis\n  * infected ulcer (see exclusion criteria for important qualifications)\n  * wound infections\n* Patients must be expected to require at least 7 days of intravenous antibiotic treatment\n\nExclusion Criteria:\n\n* Received more than 24 hours of potentially effective systemic (IV, IM or PO) antibiotic therapy prior to randomization\n* Burns involving \\> 20% of body surface area or third-degree/full-thickness in nature, diabetic foot ulcers, ischemic ulcers/wounds, necrotizing fascitis, gas gangrene, or mediastinitis.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Clinical Response","description":"The Clinical Response for each patient was determined by the investigator by assessing a patient's clinical signs and symptoms at the specified evaluation compared with the Baseline evaluation. Cure: resolution of signs and symptoms associated with the skin infection present at study admission such that no further antibiotic therapy was necessary; Not Cured: inadequate response to study therapy; Indeterminate: unable to determine outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"323","spread":null},{"groupId":"OG001","value":"321","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"34","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":31,"n":426},"commonTop":["Nausea","Dysgeusia","Headache","Vomiting","Insomnia"]}}}